TIDMVAL
RNS Number : 6992Y
ValiRx PLC
04 January 2024
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY
THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER
ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS AMED BY
REGULATION 11 OF THE MARKET ABUSE (AMMENT) (EU EXIT) REGULATIONS
2019/310 . UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA REGULATORY
INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
4 January 2024
VALIRX PLC
("ValiRx" or the "Company")
Result of General Meeting
Issue of Equity and Total Voting Rights
Director and PDMR Shareholding
ValiRx plc (the "Company") (AIM: VAL), announces that, further
to the Conditional Fundraise & Notice of General Meeting
announcement dated 13 December 2023, at its General Meeting held
earlier today, resolutions 1 and 3 were duly passed and resolution
2 was not passed. Details of the votes received in respect of the
resolutions will be available shortly on the Company's website.
Director and PDMR Shareholdings
Following completion of the Fundraising, the shareholdings of
the Directors and PDMRs who participated in the Fundraising are set
out in the table below:
Beneficial
Beneficial shareholding
Fundraising shareholding as a percentage
Existing beneficial Shares subscribed on completion of the Enlarged
Director/PDMR shareholding for of the Fundraising Share Capital
Suzanne Dilly 416,668 66,666 483,334 0.37%
Kevin Cox 372,333 150,000 522,333 0.39%
Gerry Desler 128,668 66,666 195,334 0.15%
Martin Lampshire 144,000 150,000 294,000 0.22%
Stella Panu - 333,333 333,333 0.25%
Cathy Tralau-Stewart - 66,666 66,666 0.05%
Issue of Equity
The Placing Shares, the Subscription Shares and the Retail Offer
Shares have been allotted, conditional upon Admission, and
application has been made to the London Stock Exchange for, in
aggregate, 30,029,063 Placing Shares, Subscription Shares and
Retail Offer Shares to be admitted to trading on AIM. Admission is
expected to occur at 8.00 a.m. on 8 January 2024, with dealings in
the Placing Shares, the Subscription Shares and the Retail Offer
Shares commencing at the same time. The Placing Shares, the
Subscription Shares and the Retail Offer Shares will rank pari
passu with all other issued Shares.
The Fundraising remains conditional, inter alia, upon Admission
and the Placing Agreement not being terminated in accordance with
its terms.
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency
Rules, following Admission the enlarged issued share capital of the
Company will comprise 132,348,673 ordinary shares of 0.1 pence
each. The Company does not hold any shares in the treasury. The
above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company, under the Disclosure Guidance and Transparency Rules.
Capitalised terms used in this announcement have the meaning
given to them in the Conditional Fundraise, Notice of General
Meeting announcement dated 13 December 2023, unless otherwise
defined in this announcement.
The Directors of the Company take responsibility for this
announcement.
For more information, please contact:
ValiRx plc Tel: +44 (0) 2476 796496
www.valirx.com
Dr Suzanne Dilly, CEO Suzanne.Dilly@valirx.com
V Formation (Public Relations) +44 (0) 115 787 0206
www.vformation.biz
Lucy Wharton - Senior PR Executive
Sue Carr - Director lucy@vformation.biz
sue@vformation.biz
--------------------------
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Adviser) 0880
Liam Murray/Jo Turner/Ludovico Lazzaretti
--------------------------
Cavendish Capital Markets Limited Tel: +44 (0) 20 7397
(Joint Broker) 8900
Dale Bellis/Michael Johnson (Sales)
Callum Davidson/Giles Balleny (Corporate
Finance)
--------------------------
Turner Pope Investments (Joint Broker) Tel: +44 (0) 20 3657
James Pope / Andy Thacker 0050
--------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------- --------------------------------------------------------------------------------------------------------------
a. Name a) Suzanne Dilly
b) Kevin Cox
c) Gerry Desler
d) Martin Lampshire
e) Stella Panu
f) Cathy Tralau-Stewart
-------------------------------------------------------------------
2 Reason for
notification
----------------------------------------- -------------------------------------------------------------------
a. Position/Status a) Director
b) Director
c) Director
d) Director
e) Director
f) PDMR
----------------------------------------- -------------------------------------------------------------------
b. Initial notification/ Initial notification
Amendment
----------------------------------------- -------------------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------------------------------------
a. Name ValiRx PLC
-----------------------------------------
b. LEI 213800VQKB9SJCQDET40
----------------------------------------- -------------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------- --------------------------------------------------------------------------------------------------------------
a. Description Ordinary Shares
of the financial
instrument, ISIN: GB00BLH13C52
type of instrument
Identification
Code
----------------------------------------- -------------------------------------------------------------------
b. Nature of the Purchase of shares as part of the Fundraising
transaction
----------------------------------------- -------------------------------------------------------------------
c. Price(s) and Price(s) Volume(s)
volume(s)
----------------------------------------- -----------------------------------------
a) 6p a) 66,666
b) 6p b) 150,000
c) 6p c) 66,666
d) 6p d) 150,000
e) 6p e) 333,333
f) 6p f) 66,666
----------------------------------------- -----------------
d. Aggregated
information N/A
- Aggregated
Volume
- Price
----------------------------------------- -------------------------------------------------------------------
e. Date of the a) 04/01/2024
transaction b) 04/01/2024
c) 04/01/2024
d) 04/01/2024
e) 04/01/2024
f) 04/01/2024
----------------------------------------- -------------------------------------------------------------------
f. Place of the Outside a trading venue
transaction
----------------------------------------- -------------------------------------------------------------------
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer
therapeutics and women's health, accelerating the translation of
innovative science into impactful medicines to improve patient
lives.
ValiRx provides the scientific, financial, and commercial
framework for enabling rapid translation of innovative science into
clinical development.
Using its extensive and proven experience in research and drug
development, the team at ValiRx selects and incubates promising
novel drug candidates and guides them through an optimised process
of development, from pre-clinical studies to clinic and
investor-ready assets.
ValiRx connects diverse disciplines across scientific,
technical, and commercial domains, with the aim of achieving a more
streamlined, less costly, drug development process. The team works
closely with carefully selected collaborators and leverages the
combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or
partnered with investors through ValiRx subsidiary companies for
further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in
October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
Cautionary statement
Certain statements made in this announcement are forward-looking
statements. Such statements are based on current expectations and
assumptions and are subject to a number of risks and uncertainties
that could cause actual events or results to differ materially from
any expected future events or results expressed or implied in these
forward-looking statements. Persons receiving this announcement
should not place undue reliance on forward-looking statements.
Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or
revise any forward-looking statements, whether as a result of new
information, future developments or otherwise.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMEADFLELSLEFA
(END) Dow Jones Newswires
January 04, 2024 08:48 ET (13:48 GMT)
Grafico Azioni Valirx (LSE:VAL)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Valirx (LSE:VAL)
Storico
Da Mag 2023 a Mag 2024
